ARS Pharmaceuticals, Inc. (SPRY) Market Cap & Valuation Ratios
ARS Pharmaceuticals, Inc. (SPRY) has a market cap of $400.8M and a price-to-sales ratio of 3.4, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SPRYARS Pharmaceuticals, Inc.Follow SPRY — free
—
Price chart with a free account
- Market cap
- 400.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 17 Nov, in 24 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| SPRY | 0.4 | — | 3.0 | — | — | +4% | -185% | -214% |
| RGNX | 0.4 | — | 1.9 | — | — | +12% | -94% | -194% |
| ALLO | 0.4 | — | 21.4 | — | — | — | — | -52% |
| PRTA | 0.4 | — | 2.4 | — | -14.4% | +427% | -102% | — |
| ALT | 0.4 | — | — | — | — | +105% | — | -22% |
| AUTL | 0.4 | — | 1.8 | — | — | +292% | -211% | — |
| TECX | 0.4 | — | — | — | — | — | — | — |
| CCCC | 0.4 | — | 8.5 | — | — | +2% | -319% | -84% |
| AVTX | 0.4 | — | — | — | — | -87% | — | -43% |
| MPLT | 0.4 | — | — | — | — | — | — | -88% |
| EDIT | 0.4 | — | 4.5 | — | — | +21% | -161% | — |
| Median of these 10 | — | 3.5 | — | -14.4% | +21% | -161% | -68% |
; EV/Sales 3.0 vs. 3.5.
Growth vs. price
each dot a company · hover or tap for valuesARS Pharmaceuticals, Inc. — questions
- What is ARS Pharmaceuticals, Inc.'s market cap?
- $400.8M.
- What is ARS Pharmaceuticals, Inc.'s price-to-sales ratio?
- 3.4.
Every figure on this page comes from ARS Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.